Complex regional pain syndrome (CRPS) is a persistent pain condition that remains incompletely understood and challenging to treat. Historically, a wide range of different outcome measures have been used to capture the multidimensional nature of CRPS. This has been a significant limiting factor in the advancement of our understanding of the mechanisms and management of CRPS. In 2013, an international consortium of patients, clinicians, researchers, and industry representatives was established, to develop and agree on a minimum core set of standardised outcome measures for use in future CRPS clinical research, including but not limited to clinical trials within adult populations. The development of a core measurement set was informed through workshops and supplementary work, using an iterative consensus process. "What is the clinical presentation and course of CRPS, and what factors influence it?" was agreed as the most pertinent research question that our standardised set of patient-reported outcome measures should be selected to answer. The domains encompassing the key concepts necessary to answer the research question were agreed as follows: pain, disease severity, participation and physical function, emotional and psychological function, self-efficacy, catastrophizing, and patient's global impression of change. The final core measurement set included the optimum generic or condition-specific patient-reported questionnaire outcome measures, which captured the essence of each domain, and 1 clinicianreported outcome measure to capture the degree of severity of CRPS. The next step is to test the feasibility and acceptability of collecting outcome measure data using the core measurement set in the CRPS population internationally.
Introduction
Complex regional pain syndrome (CRPS) is a pain condition, usually affecting a single limb, which manifests in a wide range of sensory, motor, trophic, and autonomic abnormalities. 29 Prospective studies indicate that most cases will resolve within 6 to 13 months 4 ; however, 15% to 20% of individuals will develop a long-term disability, negatively affecting their quality of life. 21, 26 In recent years, revised diagnostic and research criteria have been published, resulting in improved standardisation across study participants. 29 Currently, however, there is no internationally agreed upon standardised core measurement set for CRPS clinical research studies in adult populations. This has limited the synthesis of clinical research evidence and consequently impeded the understanding of CRPS and potential therapeutic interventions. 41, 58 Because of the multidimensional nature of the condition, CRPS clinical studies currently use a diverse range of questionnaire outcome measures. 28 Furthermore, CRPS has recently been categorised as an "orphan disease" by the U.S. Food and Drug Administration and the European Medicines Agency, on the basis that fewer than 200,000 people in the United States, and fewer than 154,000 people in the European Union, are affected each year. 20, 55 This further highlights the importance of conducting multicentre collaborative projects to help achieve sufficient sample sizes for meaningful clinical studies.
The development of a core measurement set would facilitate the pooling and comparison of data to answer specific research Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
questions agreed upon as internationally important and relevant for the advancement of CRPS treatment. Recommending the use of the core measurement set within all clinical research studies would enable these identified research questions to be answered in an optimal and timely manner.
A core outcome measurement set can be defined as an agreed upon, standardised set of outcomes, which should be measured and reported in all clinical trials in a particular condition. 60 In recent years, core measurement sets have been increasingly developed in many health conditions in response to the inconsistency of outcome measures used in clinical trials investigating the same disease or condition. 8, 25 Utilisation of a core measurement set would reduce heterogeneity and thereby facilitate the reporting of a complete and consistent set of outcome measures across studies. 54 Previous initiatives have advocated the use of core outcome measurement sets in pain and rheumatology clinical trials: Initiative on Methods Measurement and Pain Assessment in Clinical Trials (IMMPACT) 17 and Outcome Measures in Rheumatology (OMERACT). 24 This provided a starting point for our work, because of a degree of overlap between these disorders and CRPS. The complexity and multifactorial nature of CRPS, however, necessitated the development of a core measurement set specific to this condition. Furthermore, because of the relatively low incidence of CRPS, we wished to broaden the relevance of our core set to encompass all clinical research studies, not exclusive to, but including clinical trials, so as to optimise our ability to create large study populations by combining multicentre data sets.
This article will present the first internationally agreed core measurement set recommended for use in CRPS clinical research.
Methods

The consortium
An international consortium was established in 2013, under the auspices, and with the support of the International Association for the Study of Pain (IASP) CRPS Special Interest Group, to agree upon a minimum core set of outcome measures recommended for use in all CRPS clinical studies, including clinical trials. The acronym COMPACT was agreed upon and adopted by the consortium to represent the initiative and the resultant core measurement set. COMPACT initially represented "Core Outcome Measures for complex regional PAin syndrome Clinical Trials." However, through preparation of this article, and reviewers' feedback, it was agreed by the consortium that as we are recommending this core set as appropriate for use in all clinical research studies, not exclusively for trials, then "Core Outcome Measurement set for complex regional PAin syndrome Clinical sTudies" was a more appropriate title for this core set.
The consortium comprised patients with CRPS, clinicians, researchers, and industry representatives from 15 countries: Switzerland, Germany, the Netherlands, Canada, United States, Denmark, Norway, Israel, Australia, New Zealand, South Africa, Japan, Argentina, Brazil, and United Kingdom. Members were recruited from the global CRPS community through an email invitation. Members included those with clinical or research expertise in CRPS from within an academic or clinical setting and/ or an interest in treatment outcome measures.
Patient representatives were recruited through support groups representing the United Kingdom, the Netherlands, and Switzerland. The inclusion of patient representatives, within our research team, was considered essential to ensure the core measurement set included outcome measures that were important to those with CRPS and pertinent to their experience of the condition. Kirwan et al. 35 (2003) described the value of this and the benefit of seeking a patient's perspective to gain understanding of the terms used within the outcome measures. Patient involvement, as active collaborators, contributes to the development of credible patient-reported outcome measures (PROMs), which are embedded in the patient experience. 50 Since being established in May 2014, the CRPS International Research Consortium (IRC), an organisation facilitating the pooling of resources for timely and conclusive studies (www. crpsconsortium.org), has supported COMPACT by encouraging links with other researchers. In addition, researchers wishing to use the core measurement set will be able to access it through the IRC, thereby monitoring utilisation and version control. The representation was from Grunenthal Ltd* (W1 and W3) (Opinions and views expressed by the representative from Grunenthal Ltd, were given as individual opinions, as an experienced employee within pharmaceutical industry, and not necessarily representative of Grunenthal Ltd as a whole.) and Pfizer Ltd (W1) recruited through an email invitation sent to industries working in the area of CRPS or pain.
Ethical approval and funding
The 4 workshops followed a semistructured format, (see supplementary information, available online at http://links.lww. com/PAIN/A390). Two of the authors (S.G., C.M.) chaired the workshops and/or led discussions. Each workshop, by its nature, included scheduled timeframes, where attendees worked in small groups with a clear scope and goal. Group work was fed back to all attendees for further discussion. All decisions were agreed upon by majority consensus of those present at each workshop. Figure 1 depicts the development process.
The research question
Before W1, consortium members were asked to identify research questions they wished to address to advance the treatment of CRPS. For example, these could be in relation to the identification of risk factors for the development of, or the clinical course of the condition, both of which are yet to be firmly established in CRPS. 57 The first COMPACT workshop identified a research question which required international collaboration and pooling of data, and could not be investigated without a consistent data set. It was agreed the research question should cover 3 main purposes for measurement: classification (disease/no disease), effectiveness (change over time), and prognostic indicators.
The initial research question was agreed as follows:
What is the clinical presentation and course of CRPS and what factors influence it?
Answering this question, will provide a better understanding of the potential phenotypes of CRPS, prognostic indicators, and methods of targeting therapeutic approaches. It is relevant within the context of both cross-sectional and prospective studies, including cohort studies and comparative clinical trials. The question encompasses type 1 and type 2 CRPS, and is relevant across the disease trajectory.
Domains
The minimum number of domains, or key concepts, which were considered necessary to answer the research question, was agreed upon by consensus. These provided a framework or scope which then informed the selection of appropriate questionnaire outcome measures or instruments. The OMERACT and IMMPACT initiatives were presented at W1 identifying a number of core domains which should be considered when establishing a core set of health outcome measures. 8, 54 A decision was made to use the IMMPACT core domains as a starting point, as these are recommended for chronic pain clinical trials 54 and are therefore highly applicable to CRPS, a chronic pain condition. However, to develop a robust core measurement set, a decision was made not to adopt these without confirming their applicability to CRPS, a condition somewhat unique in its features and life impacts. Both IMMPACT and OMERACT recommend particular domains which should be considered in condition-specific clinical trials. 8, 54 The domains should be appropriate for the population under investigation, measure positive and negative outcomes, and match the purpose of the clinical trial. 54 With this in mind, the consortium chose to identify CRPS-specific domains rather than directly adopt those previously identified for generic chronic pain or rheumatology studies.
Measurement tools
Selection of questionnaire outcome measures was agreed by consensus and informed by (1) a systematic literature review conducted by members of the consortium, 28 (2) a core data set used by a pre-existing Dutch clinical and academic CRPS research consortium (TREND), and (3) patient burden. The heterogeneity of outcome measures, which was apparent from the systematic review, 28 demonstrated the challenge of synthesising research evidence at an international level and even nationally. Emphasis was placed on identifying the minimum number of outcome measures (and the briefest possible), which would permit reliable assessment of the core domains, as the intention is for individual researchers to augment the core measurement set with measures specific to their investigation. A number of different questionnaires were considered for inclusion in the core measurement set (see supplementary information, available online at http://links.lww. com/PAIN/A390), many of which were identified from the systematic literature review. 28 A questionnaire was considered based on its ability to capture the key aspects of each domain, its length, and experience of its use by the workshop attendees.
Consideration was given to the development of new instruments; however, because of the time and resource required for this, existing instruments were first examined for suitability. A systematic review of the literature, which evaluated the psychometric properties of outcome measures used for CRPS, found no tool to have been fully assessed in this population, 43 and no specific tool was recommended for use in CRPS. 43 This is based on previous CRPS-specific validation, with the exception of the CRPS Severity Score. 30 In addition to hard copy questionnaire outcome measures, including those identified as a result of the literature review, consideration was also given to an electronic patient-reported outcome measurement information system (see section 2.3.5).
The measures agreed upon at W4 primarily comprised PROMs, measuring various aspects of health and function identified as important to the CRPS patient and applicable to the research question. The only addition to these PROMs was a clinician-reported outcome measure to describe the severity of the condition. In the interests of time and resources, the consortium did not conduct a review of objective clinical outcome measures, for example thermal imaging to record temperature change or volumetric data to measure oedema, although we recognise the important contribution of these types of measures in CRPS clinical research. This work is planned to be conducted in the near future under the auspices of the IRC and IASP CRPS Special Interest Group. W2 and W3 considered the potential of using an existing item bank of patient-reported outcome measures: Patient-Reported Outcomes Measurement Information System (PROMIS). 13 This is a National Institute of Health (USA) funded system, which provides psychometrically sound and validated PROMs that can be used in a wide range of chronic conditions. PROMIS comprises calibrated item banks to measure diverse health concepts such as pain, physical function, and depression; these are presented for each domain as individual items and/or instruments of various lengths. In addition, PROMIS includes several collections of items, termed profiles, which measure multiple domains. For example, the PROMIS-29 Profile assesses 7 domains, each with 4 questions; depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities. 13 There is also an additional Numeric Pain intensity 0 to 10 Rating Scale (NPRS).
The PROSetta Stone initiative 14 has enabled results obtained using PROMIS items to be directly compared with many standard instruments currently used in clinical trials, such as the Short Form 36 (SF-36) or Brief Pain Inventory. Data collection using the PROMIS item bank can be captured electronically on a secure server or alternatively using a paper version. Importantly, all instruments are freely available in the public domain, and work is underway for translation and cultural validation of the profiles in multiple languages.
Modelling of the core measurement set (COMPACT)
To inform COMPACT, 3 models, comprising standard PROMs, were constructed and disseminated electronically, for consideration by the consortium. The 3 models were presented at the meeting of the IASP CRPS Special Interest Group in Buenos Aires in 2014. Feedback was collated and presented at W3. After consultation with colleagues familiar with PROMIS, a fourth model was constructed which consisted largely of PROMIS items. Feedback was collected from individuals with CRPS (n 5 5) regarding the patient burden and ease of understanding and completion of the various questionnaire models. These individuals were naïve to the development of the questionnaire, were not members of the consortium, and were native English speakers. All 4 models and the patient feedback were presented at W3.
After W3, the final draft COMPACT was presented to a UKbased focus group of patient researchers (n 5 3). The design of the document was reviewed in detail on 2 occasions, to allow revisions to be considered and then the feedback was presented to the consortium at W4. Care was taken to assess the COMPACT measures for cultural and sex sensitivity, for example, "gardening" was added to "yard work" to aid clarification and as per recommendations from PROMIS, and the date within the document was internationally formatted. The final COMPACT was agreed upon by consensus at W4.
Results
Core Outcome Measurement set for complex regional PAin syndrome Clinical sTudies (COMPACT)
The following outcome measures comprise COMPACT ( Table 1) . The domains reported in Table 1 closely reflect those recommended by IMMPACT, 54 with the addition of disease severity, catastrophizing, and self-efficacy. The outcome measures comprising COMPACT are introduced throughout the document with text designed to ensure that the respondent focuses on only those factors relevant to CRPS. For example, "the following questions ask you about the type of pain you experience due to CRPS." Respondents are asked to reflect on a specific time frame, for example "in the past 7 days."
Pain
Pain is an overarching feature of CRPS 38 and consequently should be assessed in any CRPS clinical study. A recent, international Delphi study (n 5 252), which asked people with CRPS to define their top 5 priorities for recovery supported this, identifying the top 2 priorities as no further CRPS related pain in their limb(s) and no generalised pain. 39 The dimensions of pain intensity and pain interference were considered essential for inclusion in the core measurement set to distinguish between potential subtypes of the condition. Pain intensity is most commonly used as the primary outcome measure for studies investigating chronic pain interventions. 17 When comparison is made between multiple pain ratings and a single pain rating, the latter has been demonstrated to be an accurate predictor of average pain for those with CRPS type 1. 22 The authors, therefore, recommend CRPS pain be rated as the average over the last 7 days using an item from the PROMIS-29 Profile, version 2.0. 13 A numeric rating scale will be used to measure the least and worst pain in the previous 24 hours, to capture the daily variability in its intensity. Pain interference will be measured using the 4 items within the PROMIS-29 Profile, version 2.0. 13 There is evidence that pain qualities (eg, burning, cramping, and throbbing pain) do change over the course of CRPS, 48 and therefore capturing the nature of pain qualities was also considered important with regard to identifying potential CRPS subtypes and assessing the variability of pain over time. Treatment interventions may be more effective for some pain qualities. 17 Pain qualities will be captured using the neuropathic items from the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2). 18 Permission was obtained from the author, to administer the 6 quality measures in isolation from the full version of the SF-MPQ-2. A number of questionnaire outcome measures were considered to capture this aspect of pain (Table 1) ; however, the 6 SF-MPQ-2 neuropathic items capture the essential qualities with minimum patient burden. A preliminary Rasch analysis supported the use of this subscale as a "stand-alone" assessment; 42 however, this needs to be repeated in a larger, mixed population.
Research shows that some people with CRPS experience widespread pain, 7 which could confound the assessment of CRPS-related pain. For this reason, the individual will be asked to consider and report only the pain related to the CRPS when completing the instrument. The consortium patient researchers recommended that the pain measurement tools should not be listed first within the COMPACT questionnaire set. This was judged to have the potential to place excessive focus on the pain and the negative connotations associated with this.
Disease severity score
Disease severity, measured using the CRPS Severity Score (CSS), 30 is completed by the clinician at baseline. The CSS is directly derived from the Budapest CRPS Diagnostic Criteria and will confirm the CRPS diagnosis. 29 Any clinician can complete the CSS, and no special training is required. In addition, it will provide information regarding differences in clinical presentation between individuals 10,16 and the investigation of possible subtypes of the condition. Symptoms reported by the individual and CRPS signs present on examination are recorded by the clinician. Higher scores indicate greater CRPS severity (range 0-16). 31 In addition to baseline, completion of the CSS at a minimum of one of the additional time points of 3, 6 and 12 months are recommended if possible. Completion on more than 1 occasion will enable the changing clinical aspects of CRPS over time to be captured for each individual. The CSS has been found to be responsive (effect size 1.99 [95% confidence interval 1.54-2.44], standardized response mean 5 1.42) in a sample of n 5 66 persons with CRPS followed for 1 year. 42 
Participation and physical function
Reduced function as a consequence of pain is apparent in individuals with CRPS. 6 Of these, approximately 15% will report unremitting pain and physical impairment 2 years after the onset of CRPS. 21, 47 This is supported by a recent systematic review, which found functional impairments such as weakness, stiffness, and limited range of motion persisted in the majority of patients for 1 year or more in varying severity. 4 Social participation was considered important to measure; both in relation to the limitations which may result from physical impairment but also social avoidance to prevent any accidental contact with the affected limb. 46 COMPACT will capture measures of physical function and social participation within the PROMIS-29 Profile and the EQ-5D-5L, the latter used widely, allowing comparison across chronic conditions. The PROMIS-29 Profile will also measure the constructs of fatigue and sleep quality, which may develop as a consequence of living with chronic pain. 27 Once again, the individual will be asked to consider and report how CRPS impacts on their life when completing the instrument, to reduce possible confounders related to comorbidities.
Emotional and psychological function
As a consequence of living with a long-term pain condition, psychological symptoms such as depression and anxiety may develop. 27 Although a systematic review identified no relationship between the onset of CRPS type 1 and several psychological factors, 5 some evidence suggests that the intensity of CRPS pain may be uniquely impacted by psychological distress. 3, 9, 11 Patients with comorbid chronic pain, depression, and anxiety have been shown to have worse clinical outcomes than those with pain alone. 1, 12 This domain measures anxiety and depression using the PROMIS-29 Profile. In addition, suicidal ideation will be assessed using a PROMIS item. 36, 44 3.1.5. Self-efficacy
The Pain Self-Efficacy Questionnaire (PSEQ) will be used to capture this domain. 40 The respondent considers how confident they are performing each activity, while taking their pain into account. This provides more clinically useful data than asking about performing an activity in isolation. 40 
Catastrophizing
Pain catastrophizing was considered an important dimension of the core measurement set. Multiple studies in non-CRPS populations indicate that catastrophizing is a prospective predictor of negative pain outcomes. 19, 23, 45, 49, 53 The authors recommend the Pain Catastrophizing Scale (PCS) be used to capture this domain 52 : a score of greater than 30 is believed to represent a problematic level of catastrophic thinking. 51 Bean et al. 2 reported that the average PCS score at baseline was 22.0 in their sample of 66 persons diagnosed with CRPS within the previous 12 weeks, but underwent significant reduction to a mean score of 13.4 by 6 months as treatment progressed (P , 0.001). This supports pain catastrophization as an important construct for measuring the evolution of this syndrome.
Patients global impression of change
To establish the efficacy of interventions in CRPS clinical studies, it was considered important to capture the patient's global impression of change. Respondents will be asked to rate the improvement of CRPS using a 7-point scale, ranging from "very much improved" to "very much worse." 33 3.1.8. Demographic data and health care utilisation COMPACT will include demographic data to capture the characteristics of the population such as sex, age, affected limb(s), and disease duration. Ability to participate in paid or unpaid employment and education will also be reported.
Health care utilisation was excluded from the final domains as it was considered more appropriate that individual countries adopt a local measure due to the variation in health care service systems. Reporting these data may also be affected by an individual's ability to recall clinical interactions and may be influenced by litigious processes in some countries. Use of a country-specific measure will more appropriately accommodate these cultural variations than a single generic tool.
Discussion
The international application of COMPACT will require availability in a wide range of languages. This was a consideration throughout the development process and informed the final selection of the outcome measures. Many of the selected measures are currently available in a number of translations, for example, the EQ-5D-5L 32 and Pain Catastrophizing Scale. 52 The PROMIS initiative has addressed translation and cultural validation for many of the PROMIS items, although further work is required for translation of the wide range of languages required for COMPACT. Where documents require translation, these will be undertaken by the COMPACT consortium research partners in each country under strict adherence to the requirements specified by the developers of each questionnaire or by adhering to the "best practice" translation standards established in a protocol for the CRPS Recovery Study. 37 This uses a forwards and backwards translation approach to ensure the meaning of text is the same across each of the countries.
Although the measurement properties of the PROMIS tools are assumed to be invariant across populations, 13 the proposed constellation of outcome measures included in COMPACT will require further work to ascertain their psychometric properties and develop relevant norms for the CRPS population. This will be undertaken after the feasibility and acceptability of COMPACT have been tested using data and views from the international CRPS community.
Future work will also include the development and validation of a paediatric version of COMPACT. The current version is designed for use in an adult population, although some of the measures have already been validated in children or have paediatric versions. 15, 59 The authors recognise the importance of developing safe and effective data systems to support this work. The consortium will explore the feasibility of using an existing data management system for the central collection and management of the COMPACT data. This will facilitate data sharing, meta-analysis and will allow subgroup analyses, for example, sex-based differences and CRPS subtypes.
The authors recommend COMPACT to be completed by all patients at 2 time points, baseline, and 6 months. At 3 months, our patient population may have only just initiated treatment and rehabilitation, and a recent study demonstrated the greatest change in symptom severity was in the first 6 months after CRPS onset. 2 Draft guidance for studies evaluating analgesia in chronic pain recommend a study duration of at least 3 months. 56 Additional assessments at 3 and/or 12 months are optional, and the CSS should be completed at baseline as a minimum. These time points were considered appropriate for our specific research question; however, we recognise that these recommended time points may need adjusting, or adding to, to meet study-specific requirements.
A key challenge will be to raise awareness and dissemination of the core measurement set to promote its use by those conducting CRPS clinical studies. Kirkham et al. 34 identified that 60% to 70% of rheumatology clinical trials were reporting the full OMERACT core measurement set 20 years after its introduction. Future work will include a survey of health professionals within the international CRPS community to identify which outcome measures are currently being used and then to re-evaluate this after dissemination.
Conclusion
A core measurement set for CRPS clinical studies has been agreed upon by an iterative process of consensus. This will facilitate international collaborative studies to advance our knowledge and treatment of CRPS. The next step is to test the feasibility and acceptability of COMPACT in the international CRPS population, and to identify an appropriate electronic data management system. A workshop will be convened in 2018 to review data collected from studies using COMPACT, and users' (patient and researchers) experience of COMPACT.
If researchers outside the COMPACT consortium wish to use COMPACT it can be accessed from relevant websites (eg, CRPS International Research Consortium, IASP CRPS Special Interest Group). It is asked that, if COMPACT is included in research studies, feedback is shared with the COMPACT consortium.
